What is AOD-9604?

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone. It is discussed as a lipolytic or fat-metabolism peptide, not as full growth hormone replacement. [6][7]

Direct mechanistic support is mainly preclinical, including rodent studies of fat oxidation, lipolysis, and weight gain. Public human weight-loss support is much thinner than modern GLP-1 or incretin-drug evidence. [8][9][11]

The naming can be confusing: AOD-9604 is grouped with growth-hormone fragments, while the direct obesity literature is much smaller than approved obesity-drug evidence. [10][11][5]

What AOD-9604 is investigated for

AOD-9604 evidence is grouped by practical use case and mixed research context and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Fat breakdown and metabolism

Mixed research context

32% Limited

The biology is plausible but not enough to support human weight-loss expectations. [8][11]

Human evidence

Published human efficacy support is weak and does not establish a reliable weight-loss effect. [11]

Animal / mechanistic evidence

Rodent and tissue studies support biological activity around lipolysis, beta-adrenergic signaling, and fat oxidation. [8][9][6]

Cartilage repair and osteoarthritis

Injectable

30% Limited

Cartilage repair has preclinical support for AOD-9604, but human osteoarthritis relief has not been established. [19]

Human evidence

No human osteoarthritis data establish AOD-9604 as a joint-repair treatment. [19]

Animal / mechanistic evidence

A rabbit collagenase-induced knee osteoarthritis model reported cartilage-regeneration signals after intra-articular AOD-9604, with stronger findings when combined with hyaluronic acid. [19]

Weight loss and fat loss

Mixed research context

18% Insufficient

AOD-9604 is not a proven weight-loss or fat-loss peptide. [11][10]

Human evidence

Older clinical-development discussion does not establish reliable weight-loss or fat-loss improvement in humans. [11][10]

Animal / mechanistic evidence

Preclinical fat-metabolism findings explain the interest in fat loss, but they do not translate into a confident human result. [8][9]

Evidence snapshot

Overall confidence

Limited

30%

AOD-9604 is not a high-confidence weight-loss peptide. The direct biology is mostly animal and mechanism work, while human efficacy support is weak and regulatory concerns are prominent. [8][11][2]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

24%

Human evidence

Insufficient

Public human weight-loss support is historically thin and does not establish a reliable obesity-treatment effect. [11][10]

44%

Animal / preclinical

Limited

Rodent and tissue studies support biological activity around lipolysis, fat oxidation, and weight-gain models, but those findings do not establish human outcomes. [8][9][6]

42%

Mechanism support

Limited

The mechanism rationale centers on a growth-hormone fragment domain and lipid-metabolism effects, with no modern clinical evidence package comparable to approved obesity drugs. [6][7][11]

Forms & administration

AOD-9604 has no approved-drug administration pathway. Older oral and IV development material, preclinical injection models, and current research-market injectable claims should be kept separate. [1][10][2][5]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 250-500 mcg per dose. Oral protocols use about 1 mg per day. [10][11][2]

Frequency

Injectable protocols usually use 1-2 doses daily. Oral protocols are usually once daily. [10][11]

Timing Considerations

Common timing is morning or before a workout. [10][11]

Cycle Length

Injectable cycles commonly run 8-12 weeks. Oral protocols run about 24 weeks. [10][11]

What to expect

Early weeks

Early changes are more likely to look like ordinary weight fluctuation than a clear peptide-specific fat-loss effect. [11]

8-12 weeks

A clear waist or scale change is unlikely without matching nutrition and training changes, and human evidence does not support GLP-1-like weight-loss expectations. [11]

Longer term

Large or reliable fat-loss effects remain unlikely on AOD-9604 alone; any visible change is more likely to be modest and hard to separate from the rest of the routine. [11][2]

After stopping

Weight and waist are likely to keep following nutrition, training, and baseline metabolic factors after the protocol ends, because AOD-9604 has not shown a durable reset effect in humans. [11][2]

Safety profile

AOD-9604 safety handling is dominated by product and regulatory concerns: no approved product identified, FDA compounding safety risks, limited clinical usefulness, and explicit sports prohibition. [1][2][5]

Cautions

Immunogenicity risk [2]
Impurities and characterization [2]
Athlete prohibited [5]
Pregnancy and special populations [1][2]

What we don't know

Human long-term safety, dose-response, product purity, and route-specific risk remain unresolved. [2]

Who AOD-9604 is not for

Route-specific avoid and medical-review notes:

Competitive athletes
AOD-9604 is explicitly prohibited under WADA growth hormone fragment language. [5]
Pregnancy and special populations
No approved label or robust human safety package supports use in pregnancy, breastfeeding, pediatric use, frailty, or complex endocrine disease. [1][2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Growth-hormone-axis products
Stacking AOD-9604 with growth hormone, GH secretagogues, or other weight-loss/metabolic drugs could compound or confuse appetite, weight, lipid, and adverse-effect signals; no human evidence establishes a safe or effective combination protocol. [11][2]

Pairing notes

Not recommended with

GH, GHRH, GHRP, or metabolic fat-loss stacks Mixed research context, Injectable

AOD-9604 has no validated human combination regimen with GH, GHRH, GHRP, or other weight-loss agents. Its injectable use has limited safety data, potential immunogenicity and impurity concerns, and serious adverse-event reports with unclear causality. Adding other agents introduces unstudied combination exposure, and AOD-9604 is prohibited in tested sport. [18][2][5]

Related peptides

CJC-1295 CJC-1295 (no DAC)

Regulatory status

United States

United States: not FDA-approved for human use as a drug. FDA also identifies compounded AOD-9604 safety concerns. [1][2]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Injectable AOD-9604 is not an FDA-approved human drug product. [1][2]	Flagged FDA lists compounded AOD-9604 among substances with potential safety risks, including immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, and limited safety information. [2][3]

Injectable

FDA drug approval

Not Approved

Injectable AOD-9604 is not an FDA-approved human drug product. [1][2]

503A compounding

Flagged

FDA lists compounded AOD-9604 among substances with potential safety risks, including immunogenicity for certain routes, peptide-related impurities, API-characterization complexity, and limited safety information. [2][3]

International

International status varies, but sports status is not ambiguous under WADA: AOD-9604 is named as a prohibited growth hormone fragment. [5]

Sports & competition

AOD-9604 is prohibited for athletes under WADA growth hormone fragment language, and WADA has issued specific public statements on the substance. [5][4]

How it works

AOD-9604 is a growth-hormone fragment built around lipid-metabolism interest, not full GH replacement. The strongest signal is preclinical fat oxidation and lipolysis biology, which keeps the page in a low-confidence bucket. [6][8][9]

That mechanism does not establish human fat loss. Older oral, injected, and experimental contexts are not interchangeable, and the obesity-development story did not become an approved therapy. Human usefulness remains the weak link. [11][10][1]

FDA compounding concerns and WADA growth-hormone-fragment language make the mechanism a caution point, not reassurance for self-use, stacking, tested athletes, or a clinical protocol. [2][5]

Research gaps & open questions

What the current literature has not yet settled about AOD-9604:

Peer-reviewed, placebo-controlled trials still need to show whether AOD-9604 produces meaningful, lasting weight loss in people and which dose and route were used. [11]

Each route needs direct studies of how the body handles AOD-9604, whether immune reactions occur, and what happens with long-term exposure; product purity also needs reliable testing. [2]

For athletes, the practical unanswered question is how product contamination and use affect testing risk; the anti-doping rule is clearer than the weight-loss evidence. [5]

Common questions

Is AOD-9604 the same as growth hormone?

No. It is a synthetic fragment analog related to the C-terminal region of human growth hormone, not full growth hormone replacement. [6]

Does AOD-9604 work for weight loss?

Published evidence does not support strong human weight-loss confidence. Most direct support is preclinical, with weak public clinical usefulness compared with approved obesity drugs. [8][11]

Is AOD-9604 banned in sport?

Yes. WADA explicitly names growth hormone fragments including AOD-9604 in the prohibited list. [5]

Myths & misconceptions

Myth

Because AOD-9604 is only a fragment, it is automatically safe.

Reality

A smaller fragment does not eliminate product-quality, immune, regulatory, or anti-doping risks. FDA specifically flags compounded AOD-9604 safety concerns. [2]

Myth

Rodent fat-loss studies prove human fat loss.

Reality

Rodent lipolysis and fat-oxidation findings are biological plausibility, not proof of meaningful human weight loss. [8][11]

Myth

If it is not a steroid, it is not banned.

Reality

WADA prohibits many peptide hormones, growth factors, related substances, and fragments; AOD-9604 is explicitly named. [5]

History & discovery

AOD-9604 moved from growth-hormone-fragment lipid-metabolism research into obesity-drug interest, then into anti-doping and compounding controversy. Its reputation grew wider than the human outcome evidence, so the useful history is cautionary. [6][10][11][2]

Early rodent and lipid-metabolism papers framed AOD-9604 as a synthetic growth-hormone fragment, and later development summaries described it as a metabolic obesity-drug candidate, but approval did not follow. [6][8][10][11]

WADA and FDA materials shifted the practical history toward sports eligibility, product quality, and compounding risk rather than treating the early GH-fragment mechanism as clinical validation. [4][2][5]

Published research 17 studies

[1]

openFDA Drugs@FDA query for AOD-9604

openFDA / U.S. Food and Drug Administration. database query.

[2]

Certain bulk drug substances for use in compounding may present significant safety risks

U.S. Food and Drug Administration. regulatory.

[3]

Bulk drug substances nominated for use in compounding under section 503A

U.S. Food and Drug Administration. regulatory.

[4]

WADA statement on substance AOD-9604

World Anti-Doping Agency. regulatory.

[5]

The 2026 Prohibited List

World Anti-Doping Agency, 2025. regulatory.

[6]

Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism

American Journal of Physiology-Endocrinology and Metabolism. animal.

[7]

Metabolic studies of a synthetic lipolytic domain of human growth hormone in obese Zucker rats

Endocrinology / metabolic research. animal.

[8]

The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism in obese mice

Endocrinology. animal.

[9]

Increase of fat oxidation and weight loss in obese mice caused by a fragment of human growth hormone

American Journal of Physiology-Endocrinology and Metabolism. animal.

[10]

AOD-9604 Metabolic

Drugs in R&D. review.

[11]

Obesity pharmacotherapy: current perspectives and future directions

Current Obesity Reports / PMC. review.

[12]

Detection and in vitro metabolism of AOD9604

Drug Testing and Analysis. in vitro.

[13]

Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors

Obesity (Silver Spring, Md.), 2006. review.

[14]

Obesity drugs in clinical development

Current opinion in investigational drugs (London, England : 2000), 2006. review.

[15]

Gateways to clinical trials

Methods and findings in experimental and clinical pharmacology, 2005. review.

[16]

AOD-9604 does not influence the WADA hGH isoform immunoassay

Drug testing and analysis, 2013. in vitro.

[17]

Current updates in the medical management of obesity

Recent patents on endocrine, metabolic & immune drug discovery, 2012. review.